Mentoring and Research in Placebo Studies, Asian Medicine and CAM

描述(由申请人提供)：目标：本提案申请职业生涯中期K24奖，为Ted Kaptchuk博士提供保护时间，以1)稳定和扩大他对初级研究人员的指导，主要是在安慰剂研究领域，其次是亚洲医学和CAM，以及2)增加他在基础和社会科学以及生物伦理学方面的研究技能，以增强他领导安慰剂研究创新项目的能力。背景：关于安慰剂、医疗仪式和患者-医生关系对健康结果的影响的研究往往被边缘化。这笔赠款旨在加强PI的议程，即使用科学方法来调查这些构成所有治愈的医学成分。重要的是，这笔赠款还寻求开发多学科方法，将基础科学、临床科学和社会科学结合起来，以促进临床翻译，并抵消仅来自单一学科的方法或理论对问题施加的偏见或限制。应聘者具有独特的背景和丰富的经验，在多个R01和R21上担任PI或联合PI，作为P01和U19的项目负责人，以及在其他R01、R21和U01上的联合调查员。他已经在指导K01、K23、R21和U19受赠者以及培养初级研究人员方面取得了成功的记录。环境：哈佛大学丰富的研究环境，以及高盛、古德、罗森、克莱曼、波特拉基斯、布林、哈林顿、菲利普斯和戴维斯等杰出哈佛教授的积极投入，为候选人的议程创造了一个独特的框架。指导计划：作为哈佛医学院(HMS)跨部门安慰剂网络和HMS亚洲医学计划的主席，PI创建了独特的结构，吸引了来自哈佛许多研究机构和主要教学医院的初级研究人员和知名资深教师。此外，作为HMS由NCCAM资助的T32 CAM奖学金计划的副主任，PI是所有CAM领域的初级研究人员的资源。培训：生物伦理学和基础生物及社会科学方面的实践培训和正规教学将增强候选人领导多学科团队的能力。研究：候选人建议扩展一项成功的大型随机对照试验(n=287)，该试验评估安慰剂效应是否可以以“剂量依赖”的方式给予，以探索几个可测试的机制假说，即安慰剂反应是否可以归因于生理、心理、遗传、社会学和人类学变量。意义：这款K24将支持下一代研究人员，并帮助为P01和R01未来在安慰剂研究中的多学科应用提供科学和制度框架。

DESCRIPTION (provided by applicant): Goal: This proposal requests a Midcareer K24 award to provide Dr. Ted Kaptchuk with protected time to 1) stabilize and expand his mentoring of junior investigators primarily in the domain of placebo studies and secondarily, in Asian medicine and CAM, and 2) increase his research skills in the basic and social sciences and in bioethics to enhance his capacity to lead innovative projects in placebo studies. Background: The study of the impact of placebo, medical ritual and the patient-practitioner relationship on health outcomes is often marginalized. This grant seeks to strengthen the Pi's agenda of using scientific methodologies to investigate these components of medicine that underlie all healing. Importantly, this grant also seeks to develop multi-disciplinary approaches that incorporate basic, clinical and social sciences to foster clinical translation and to counteract bias or limitations imposed by methods or theories brought to the problem from only a single discipline. Qualifications: The candidate has a unique background and extensive experience as PI or co-Pi on multiple R01s and R21s, as project leader for a P01 and a U19, and co-investigator on other R01s, R21s and U01s. He already has a successful track record in mentoring K01, K23, R21 and U19 grantees and nurturing junior researchers. Environment: Harvard University's rich research environment and the active commitment of such distinguished Harvard professors as Drs. Goldman, Good, Rosen, Kleinman, Pothoulakis, Buring, Harrington, Phillips and Davis create a unique framework for the candidate's agenda. Mentoring Program: As chair of Harvard Medical School's (HMS) cross-departmental Placebo Network and HMS' Program in Asian Medicine, the PI has created unique structures that attract both junior investigators and established senior faculty from Harvard's many research institutions and major teaching hospitals. Also, as associate director of a well-established NCCAM-funded T32 CAM fellowship program at HMS, the PI is a resource for junior researchers across all CAM domains. Training: Hands-on training and formal didactic learning in bioethics and the basic biological and social sciences will strengthen the candidate's ability to lead multi-disciplinary teams. Research: The candidate proposes to extend a large successful RCT (n=287), that evaluates whether placebo effects can be administered in a "dose dependent" manner to explore several testable mechanistic hypotheses on whether placebo response can be attributed to physiological, psychological, genetic, sociological and anthropological variables. Significance: This K24 will support a future generation of investigators and help provide the scientific and institutional framework for future multi-disciplinary P01 and R01 applications in placebo studies by the Principle Investigator.